Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

• Status: Terminated
• Trial end date: 2018-06-29
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study GS-US-312-117.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Idelalisib

Criteria

Key Inclusion Criteria:

• Individuals in the primary Phase 3 study (Study GS-US-312-0116) who are compliant

• Tolerating primary study therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.